Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

rSIFN co

Next Previous
Drug Profile

rSIFN co

Alternative Names: Artificial recombinant super-compound interferon; Crystalline recombinant interferon; Recombinant super compound interferon; Recombinant super interferon compound; rSIFN-co

Latest Information Update: 10 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Huiyang Life Science and Technology Corporation
  • Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Interferon alpha replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II COVID 2019 infections
  • Phase I Solid tumours

Most Recent Events

  • 25 Feb 2025 Sichuan Huiyang Life Science and Technology Corporation plans a phase II trial in Solid tumours (NCT02464007)
  • 30 Nov 2024 Sichuan Huiyang Life Science and Technology Corporation terminates a phase-I clinical trials in Solid tumours (Late-stage disease) in USA (SC) due to protocol amendment(NCT02464007)
  • 08 Aug 2022 rSIFN-co is still in phase-I trial in Solid tumours (Late-stage disease) in USA (SC) (NCT02464007)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top